The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat people suffering from Sickle Cell Disease.
Ergomed Chief business officer Andrew Mackie tells Proactive: ”It’s great news for us. The Independent Data Safety Monitoring Board have had a look at the first 25 patients included in the study and they’ve concluded that it’s safe to continue.”
”Also, because of the safety profile seen so far they’ve actually allowed us to open up the recruitment to young patients – this will enable us to increase the pace of recruitment in the study … and ultimately when it gets to market it will be able to serve a wider population”.
Top line are results now expected in the first half of 2018 rather than in the first half of next year.
Story by ProactiveInvestors